Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics, Inc. has launched the Myriad Collaborative Research Registry (MCRR), formerly known as the Precise Treatment Registry. The MCRR is a comprehensive pan-cancer registry with data from over one million patients, encompassing germline and tumor testing results from Myriad's cancer products. This registry is one of the largest of its kind and is freely available for research to promote clinical data sharing and advance the field of precision medicine.
December 20, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics has established the MCRR, enhancing its position in genetic testing and precision medicine with a large-scale, freely available cancer registry.
The launch of the MCRR by Myriad Genetics is likely to be viewed positively by investors and the medical community, as it demonstrates the company's commitment to advancing precision medicine and cancer research. The registry's scale and the fact that it is freely available for research use could potentially lead to new partnerships, enhance the company's reputation, and possibly drive future revenues through increased usage of their testing products.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90